Assistant Professor, Oncologic Sciences, USF-Morsani
General Surgery
Dr. Pamela J. Hodul, MD
|
|
Give Review
Pamela J. Hodul, MD practices General Surgery. She studied medicine at Loyola University Chicago Stritch School of Medicine. She received awards:"Fellow". Pamela J. Hodul is a published doctor. She has 29 papers published. The most current publication "Outcomes of resected pancreatic cancer in patients age 70." Doctor Pamela J. Hodul, MD is registered with Medicare.
Publications
- Outcomes of resected pancreatic Cancer in patients age ≥70.
- Resected pancreatic Cancer outcomes in the elderly.
- Long-term outcomes of inDuction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
- Comparative long-term outcomes of upfront resected pancreatic Cancer after preoperative biliary drainage.
- Familial Gastrointestinal Stromal Tumor Syndrome: Report of 2 Cases With KIT Exon 11 Mutation.
- Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine Tumors: a single-center experience.
- Adjuvant radiotherapy and lymph node dissection in pancreatic Cancer treated with surgery and chemotherapy.
- Stereotactic Body Radiation Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer Is Effective and Well Tolerated.
- Vitamin E ?-Tocotrienol Induces p27(Kip1)-Dependent Cell-Cycle Arrest in Pancreatic Cancer Cells via an E2F-1-Dependent Mechanism.
- High-grade dysplasia and adenocarcinoma are frequent in side-branch intraDuctal papillary mucinous neoplasm measuring less than 3 cm on endoscopic ultrasound.
- Central pancreatectomy for benign pancreatic lesions.
- Comparison of 1-, 2-, and 3-Dimensional Tumor Response Assessment After Neoadjuvant GTX-RT in Borderline-Resectable Pancreatic Cancer.
- Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic Cancer.
- RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms.
- Biology and treatment of metastatic gastrointestinal neuroendocrine Tumors.
- Aggressive surgical resection in the management of pancreatic neuroendocrine Tumors: when is it indicated?
- Outcomes following resection of pancreatic adenoCarcinoma: 20-year experience at a single institution.
- Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic Cancer.
- TNM staging is obsolete.
- The role of cytoreDuctive hepatic surgery as an adjunct to the management of metastatic neuroendocrine carcinomas.
- Octreotide does not prevent postoperative pancreatic fistula or mortality following Pancreaticoduodenectomy.
- The effect of preoperative Biliary stenting on postoperative complications after pancreaticoduodenectomy.
- Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomy.
- A comparison of pancreaticogastrostomy and pancreaticojejunostomy following pancreaticoduodenectomy.
- Dimethyl 2-[[2-(methoxycarbonyl)-1-(methoxycarbonylmethyl)pyrrol-4-yl]methylene]propanedioate.
- Age is not a contraindication to pancreaticoduodenectomy.
- Defining a role for endoscopic ultrasound in staging periampullary Tumors.
- Dimethyl (1-methyl-1,3-benzimidazol-5-yl)aminomethylenepropanedioate monohydrate.
Schools
Loyola University Of ChicagoStritch School Of Medicine
Loyola University Chicago Stritch School Of MedicineSurgery
Clinical Fellow H Lee Moffitt Cancer Center amp Research InstituteSurgical Oncology
Research Fellow H Lee Moffitt Cancer Center amp Research InstituteSurgical Oncology
Bs University Of MichiganNeuropsychology
Procedures Preformed
- Adrenalectomy
- Appendectomy, Laparoscopic
- Appendectomy, Open
- Biliary Drainage
- View All
Conditions Treated
- Abdominal Pain
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anal Fissure
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- Fellow
Education
-
Loyola University -
Loyola University Chicago Stritch School of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1134166085 | |
| NPPES Provider LastName | HODUL | |
| NPPES Provider FirstName | PAMELA | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | Surgical Oncology | |
| Total Claim Count | 164.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 7.93 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1134166085 |
| Last Name Of The Provider | HODUL |
| First Name Of The Provider | PAMELA |
| View All |
Similar Doctors
|
Dr. Vanessa L. Prowler, MD |
|
|
Dr. Abraham S. Marcadis, MD |
|
|
Dr. Meira M. Pernicone, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Amod Sarnaik, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Sharad I. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Larry C. Carey, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Thomas J. Krizek, MD |
|
|
Dr. Nasreen A. Vohra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dick R. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kyle B. Potts, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John P. Leone, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Livingstone S. Dore Jr., MD |
|
|
Dr. Lillian G. Dawes, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Colleen E. Jakey, MD |
|
|
Dr. Cristen N. Litz, MD |
|
|
Dr. Jonathan S. Ratcliff, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eduardo P. Layug, MD
This Doctor is OpenDoctor Recommended.
|